Products | AbbVie - Pharmaceutical Research & Development
WEBOct 28, 2021 · AbbVie discovers and delivers innovative medicines and solutions that enhance people’s lives.
Pharmaceutical Research & Development | AbbVie
WEBOct 28, 2021 · AbbVie pharmaceuticals combines advanced science with expertise to make strides in drug and treatment discovery, making a remarkable impact on people's lives.
Allergan Aesthetics | An AbbVie Company
WEBAllergan Aesthetics develops, manufactures, and markets a portfolio of leading brands and products including facial injectables, body contouring, plastics, skin care, and more.
Products - Our Science - AbbVie
WEBProducts. We recognize that patients have questions. They face struggles and enjoy triumphs as they work to improve their health – and their lives. A patient's journey is not easy. We want to help. And that's why we provide valuable treatment options for serious health challenges. For every stage of the journey, we work to improve the quality ...
U.S. FDA Approves VRAYLAR® (cariprazine) as an Adjunctive
WEBDec 16, 2022 · Cariprazine is marketed as VRAYLAR ® in the U.S., and in addition to being approved as an adjunctive therapy to antidepressants for the treatment of MDD in adults, it is FDA-approved to treat adults with depressive, acute manic and mixed episodes associated with bipolar I disorder, as well as schizophrenia.
U.S. FDA Approves QULIPTA® (atogepant) for Adults With Chronic …
WEBApr 17, 2023 · Since its initial approval for the preventive treatment of episodic migraine in September 2021, QULIPTA has been prescribed for nearly 200,000 patients. BOTOX® (onabotulinumtoxinA) is the first FDA-approved, preventive treatment for adult patients with chronic migraine.
AbbVie | Medical Information Website
WEBThis site is an online medical resource that provides access to the most current, accurate, and evidence-based information about AbbVie products.
AbbVie - Wikipedia
WEBThe company's primary product is Humira (adalimumab) ($14 billion in 2023 revenues, 27 percent of total), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohn's disease, plaque psoriasis, and ulcerative colitis.
AbbVie Inc. Company Information - Drugs.com
WEBJun 18, 2024 · AbbVie Inc. manufactures, markets and/or distributes more than 121 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not …
AbbVie Launches PRODUODOPA® (foslevodopa/foscarbidopa) …
WEBJan 9, 2024 · PRODUODOPA is the first-and-only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of severe motor fluctuations in people living with advanced Parkinson's disease whose symptoms are …